Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured acceptance of an abstract for presentation at the American ...

Second-highest abstract submissions on record, 96 live oral presentations, more than 400 posters, and global leaders ...

In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a ...

First podium presentation of IDE Clinical Trial Data of Novel Embolic Device to Treat Cancer The SIR clinical community ...

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, today announced that it will present two ...

BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare ...

(MENAFN- GlobeNewsWire - Nasdaq) -- Chiesi's abstract presentations will focus on clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- These scientific ...

-- These scientific contributions in lysosomal storage disorders (LSDs) underscore a sustained investment in data generation, patient-centered research, and authentic rare disease representation -- ...

The Israel Museum opens its new winter fare with ancient charts, abstract paintings, compelling graphics, and alfresco beauty.

-- Chiesi’s abstract presentations will focus on clinical insights and patient-reported outcomes inFabry disease and alpha-mannosidosis -- -- These scientific contributions in lysosomal storage ...

Medicare Part B IV/RPT administrations rose from 529 (2013) to 12,395 (2023), with diagnostic/interventional radiology leading volume, followed by nuclear medicine, radiation oncology, and medical ...